A Phase 2 interventional study of Quizartinib in Leukemia, Myeloid, Acute, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 27 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-02-17.
Sponsored by Daiichi Sankyo Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 20th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 2, and was the 11th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Netherlands
Ages 1 mo–18 yrs
Kura Oncology, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 5
First in 2007; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 69 across the 28 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Daiichi Sankyo Co., Ltd., one of the names counted as Daiichi Sankyo. Under that name alone:
Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo: 1 open now, 3 under way, 1 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2016, is one of 4 in phase 2, and was the 14th registered.
Daiichi Sankyo’s Leukemia, Myeloid, Acute studies by the year they started, since 1999.
1 of the studies testing quizartinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 21 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multi-center, open-label study to evaluate the efficacy, safety and pharmacokinetics of quizartinib monotherapy in Japanese subjects with FLT3-ITD positive refractory or relapsed acute myeloid leukemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
Drug: Quizartinib
Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.
Drug: Quizartinib
Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
Composite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
The composite complete remission (CRc) rate is defined as the proportion of participants whose best response is complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) after treatment with quizartinib.
Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 up until the end of treatment, except for responses from any subsequent AML therapy including transplantation
Best Response After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Best response is defined as the best measured response over all response assessments (complete response \[CR\], CR with incomplete platelet recovery \[CRp\], CR with incomplete hematological recovery \[CRi\], partial remission \[PR\], no response \[NR\], or Unknown) at all time points after the first dose of the study drug to the end of treatment (does not include response from any subsequent AML therapy including transplantation).
Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML
Response Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML
Duration of Composite Complete Remission (CRc) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Duration from the date of first composite complete remission (CRc) (complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) observed to the date of documented relapse was assessed.
Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 up until the end of treatment, except for responses from any subsequent AML therapy including transplantation
Overall Survival (OS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
OS is defined as the time from registration (enrollment) until death from any cause.
Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 1 year
Event-free Survival (EFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Event-free survival is defined as the time from date of registration until documented refractory disease, relapse after response of composite complete remission (CRc = complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]), or death from any cause, whichever occurs first.
Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 32 weeks
Leukemia-free Survival (LFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Leukemia-free survival (LFS) is the time from the first documented response of CRc until documented relapse or death from any cause. The analysis for LFS will be conditional on the participant having a documented best response of CRc.
Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 28 weeks
Hematopoietic Stem Cell Transplantation Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Proportion of participants who start hematopoietic stem cell transplantation (HSCT) immediately after the end of treatment with the study drug without receiving other treatment for AML, except for conditioning regiment for HSCT, was assessed.
Time frame: Up to new AML treatment or 1 year post treatment
Change in the Area Under the Plasma Concentration Time Curve (AUC) of Quizartinib and Its Active Metabolite After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame: Cycle 1, Days 1 and 15; Cycle 2, Day 1
Change in the Maximum Plasma Concentration (Cmax) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame: Cycle 1, Days 1 and 15; Cycle 2, Day 1
Change in the Trough Plasma Concentration (Ctrough) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame: Cycle 1, Day 15
Change in the Time to Reach Maximum Plasma Concentration (Tmax) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame: Cycle 1, Days 1 and 15; Cycle 2, Day 1
A total of 37 participants who met all inclusion and no exclusion criteria were enrolled in the study.
| Milestone | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib |
|---|---|---|
| Started | 34 | 3 |
| Completed | 9 | 0 |
| Not completed | 25 | 3 |
| Withdrew: Required stem cell transplant | 13 | 2 |
| Withdrew: Progressive disease | 11 | 1 |
| Withdrew: Adverse event | 1 | 0 |
The composite complete remission (CRc) rate is defined as the proportion of participants whose best response is complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) after treatment with quizartinib.
| percentage of participants | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Composite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML | 56.5 (37.5 to 74.2) | 33.3 (1.7 to 86.5) | 53.8 (36.2 to 70.8) |
Best response is defined as the best measured response over all response assessments (complete response \[CR\], CR with incomplete platelet recovery \[CRp\], CR with incomplete hematological recovery \[CRi\], partial remission \[PR\], no response \[NR\], or Unknown) at all time points after the first dose of the study drug to the end of treatment (does not include response from any subsequent AML therapy including transplantation).
| Participants | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Complete response (CR) | 0 | 0 | 0 |
| Complete response with incomplete platelet (CRp) | 1 | 0 | 1 |
| Complete response with incomplete hematologic(CRi) | 12 | 1 | 13 |
| Partial remission (PR) | 6 | 1 | 7 |
| No response (NR) | 5 | 1 | 6 |
| percentage of participants | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Response Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML | 79.2 (57.8 to 92.9) | 66.7 (9.4 to 99.2) | 77.8 (57.7 to 91.4) |
Duration from the date of first composite complete remission (CRc) (complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) observed to the date of documented relapse was assessed.
| weeks | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Duration of Composite Complete Remission (CRc) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML | 16.1 (4.7 to 24.6) | NA (NA to NA) | 16.1 (4.7 to 24.6) |
OS is defined as the time from registration (enrollment) until death from any cause.
| weeks | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Overall Survival (OS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML | 34.1 (27.1 to NA) | NA (22.6 to NA) | 34.1 (27.1 to NA) |
Event-free survival is defined as the time from date of registration until documented refractory disease, relapse after response of composite complete remission (CRc = complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]), or death from any cause, whichever occurs first.
| weeks | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Event-free Survival (EFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML | 12.7 (0.1 to 24.7) | 0.1 (0.1 to NA) | 12.7 (0.1 to 24.7) |
Leukemia-free survival (LFS) is the time from the first documented response of CRc until documented relapse or death from any cause. The analysis for LFS will be conditional on the participant having a documented best response of CRc.
| weeks | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Leukemia-free Survival (LFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML | 16.1 (4.7 to 24.6) | NA (NA to NA) | 16.1 (4.7 to 24.6) |
Proportion of participants who start hematopoietic stem cell transplantation (HSCT) immediately after the end of treatment with the study drug without receiving other treatment for AML, except for conditioning regiment for HSCT, was assessed.
| Percentage of participants | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Hematopoietic Stem Cell Transplantation Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML | 37.9 (20.7 to 57.7) | 33.3 (0.8 to 90.6) | 37.5 (21.1 to 56.3) |
| ng*h/mL | Quizartinib 20 mg/Day (With Use of Strong CYP3A4 Inhibitor) | Quizartinib 30 mg/Day (With No Use of Strong CYP3A4 Inhibitor) | Quizartinib 30 mg/Day (With Use of Strong CYP3A4 Inhibitor) | Quizartinib 60 mg/Day (With No Use of Strong CYP3A4 Inhibitor) |
|---|---|---|---|---|
| Cycle 1, Day 1; Quizartinib (n=3,34,0,0) | 877 ± 489 | 1170 ± 716 | — | — |
| Cycle 1, Day 1; Active Metabolite (n=3,34,0,0) | 75.1 ± 80.6 | 560 ± 391 | — | — |
| Cycle 1, Day 15; Quizartinib (n=3,32,0,0) | 2610 ± 693 | 3970 ± 2610 | — | — |
| Cycle 1, Day 15; Active Metabolite (n=3,32,0,0) | 430 ± 276 | 3120 ± 1300 | — | — |
| Cycle 2, Day 1; Quizartinib (n=0,0,2,21) | — | — | 2960 ± 749 | 9240 ± 6090 |
| Cycle 2, Day 1; Active Metabolite (n=0,0,2,21) | — | — | 983 ± 389 | 6530 ± 2630 |
| ng/mL | Quizartinib 20 mg/Day (With Use of Strong CYP3A4 Inhibitor) | Quizartinib 30 mg/Day (With No Use of Strong CYP3A4 Inhibitor) | Quizartinib 30 mg/Day (With Use of Strong CYP3A4 Inhibitor) | Quizartinib 60 mg/Day (With No Use of Strong CYP3A4 Inhibitor) |
|---|---|---|---|---|
| Cycle 1, Day 1; Quizartinib (n=3,34,0,0) | 48.1 ± 25.9 | 76.9 ± 46.8 | — | — |
| Cycle 1, Day 1; Active Metabolite (n=3,34,0,0) | 3.92 ± 4.49 | 29.1 ± 20.9 | — | — |
| Cycle 1, Day 15; Quizartinib (n=3,32,0,0) | 127 ± 35.9 | 211 ± 132 | — | — |
| Cycle 1, Day 15; Active Metabolite (n=3,32,0,0) | 18.9 ± 12.1 | 146 ± 60.4 | — | — |
| Cycle 2, Day 1; Quizartinib (n=0,0,2,21) | — | — | 149 ± 38.2 | 480 ± 296 |
| Cycle 2, Day 1; Active Metabolite (n=0,0,2,21) | — | — | 43.7 ± 17.7 | 298 ± 118 |
| ng/mL | Quizartinib 20 mg/Day (With Use of Strong CYP3A4 Inhibitor) | Quizartinib 30 mg/Day (With No Use of Strong CYP3A4 Inhibitor) | Quizartinib 30 mg/Day (With Use of Strong CYP3A4 Inhibitor) | Quizartinib 60 mg/Day (With No Use of Strong CYP3A4 Inhibitor) |
|---|---|---|---|---|
| Cycle 1, Day 15; Quizartinib | 98.2 ± 19.7 | 128 ± 92.5 | — | — |
| Cycle 1, Day 15; Active Metabolite | 17.8 ± 11.3 | 112 ± 47.9 | — | — |
| h | Quizartinib 20 mg/Day (With Use of Strong CYP3A4 Inhibitor) | Quizartinib 30 mg/Day (With No Use of Strong CYP3A4 Inhibitor) | Quizartinib 30 mg/Day (With Use of Strong CYP3A4 Inhibitor) | Quizartinib 60 mg/Day (With No Use of Strong CYP3A4 Inhibitor) |
|---|---|---|---|---|
| Cycle 1, Day 1; Quizartinib (n=3,34,0,0) | 4.08 (2.17 to 6.17) | 4.03 (1.85 to 24.20) | — | — |
| Cycle 1, Day 1; Active Metabolite (n=2,33,0,0) | 24.33 (24.25 to 24.42) | 24.32 (3.93 to 24.67) | — | — |
| Cycle 1, Day 15; Quizartinib (n=3,32,0,0) | 4.08 (4.08 to 6.25) | 3.06 (1.42 to 6.08) | — | — |
| Cycle 1, Day 15; Active Metabolite (n=3,32,0,0) | 4.08 (0 to 6.25) | 5.82 (0.83 to 24.50) | — | — |
| Cycle 2, Day 1; Quizartinib (n=0,0,2,21) | — | — | 6.17 (6.08 to 6.24) | 3.87 (0 to 6.23) |
| Cycle 2, Day 1; Active Metabolite (n=0,0,2,21) | — | — | 14.17 (4.25 to 24.08) | 5.65 (0 to 24.02) |
Collected over Adverse events were collected from the signing of the informed consent form through 45 days after last dose of study drug up to approximately 2 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Dose 30 mg/Day Quizartinib | 13/34 (38.2%) | 14/34 (41.2%) | 34/34 (100%) |
| Initial 20 mg/Day Quizartinib | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Total | 14/37 (37.8%) | 17/37 (45.9%) | 37/37 (100%) |
| Event | Initial Dose 30 mg/Day Quizartinib | Initial 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 4/34 | 2/3 | 6/37 |
| SepsisInfections and infestations | 1/34 | 1/3 | 2/37 |
| NeutropeniaBlood and lymphatic system disorders | 0/34 | 1/3 | 1/37 |
| BacteremiaInfections and infestations | 2/34 | 0/3 | 2/37 |
| CellulitisInfections and infestations | 1/34 | 0/3 | 1/37 |
| EncephalitisInfections and infestations | 1/34 | 0/3 | 1/37 |
| PneumoniaInfections and infestations | 1/34 | 0/3 | 1/37 |
| AnemiaBlood and lymphatic system disorders | 1/34 | 0/3 | 1/37 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/34 | 0/3 | 1/37 |
| HematomaVascular disorders | 1/34 | 0/3 | 1/37 |
| Event | Initial Dose 30 mg/Day Quizartinib | Initial 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| NauseaGastrointestinal disorders | 9/34 | 2/3 | 11/37 |
| Transfusion reactionInjury, poisoning and procedural complications | 0/34 | 2/3 | 2/37 |
| Platelet count decreasedInvestigations | 13/34 | 0/3 | 13/37 |
| Electrocardiogram QT prolongedInvestigations | 12/34 | 1/3 | 13/37 |
| AnemiaBlood and lymphatic system disorders | 8/34 | 1/3 | 9/37 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/34 | 1/3 | 4/37 |
| NeutropeniaBlood and lymphatic system disorders | 1/34 | 1/3 | 2/37 |
| Decreased appetiteMetabolism and nutrition disorders | 4/34 | 1/3 | 5/37 |
| HypotensionVascular disorders | 1/34 | 1/3 | 2/37 |
| ConstipationGastrointestinal disorders | 2/34 | 1/3 | 3/37 |
| Age, Categorical(Participants) | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 2 | 17 |
| >=65 years | 19 | 1 | 20 |
| Age, Continuous(years) | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Mean | 60.2 ± 14.51 | 58.0 ± 9.92 | 60.0 ± 14.68 |
| Sex: Female, Male(Participants) | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Female | 22 | 0 | 22 |
| Male | 12 | 3 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 34 | 3 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Japan | 34 | 3 | 37 |
| BMI(kg/m^2) | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Mean | 20.72 ± 2.53 | 22.25 ± 3.37 | 20.84 ± 2.58 |
| FLT3-ITD Status(Participants) | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Positive | 29 | 3 | 32 |
| Negative | 5 | 0 | 5 |
| Response to Prior Therapy(Participants) | Initial Dose 30 mg/Day Quizartinib | Initial Dose 20 mg/Day Quizartinib | Total |
|---|---|---|---|
| Relapse | 21 | 3 | 24 |
| Refractory | 13 | 0 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Dec 2016 to primary completion in Mar 2018, 15 months.
Results were first posted in Feb 2020, 1 year 10 months after primary completion. A results delay was requested in Mar 2019.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 15 months is below that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Quizartinib